Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Dyslipidemia

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 148 articles:
HTML format
Text format



Single Articles


    September 2017
  1. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Text format     Abstract available


  2. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Text format     Abstract available


  3. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Text format     Abstract available


    August 2017
  4. GITT AK, Lautsch D, Ferrieres J, De Ferrari GM, et al
    Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Atherosclerosis. 2017;266:158-166.
    PubMed     Text format     Abstract available


  5. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Text format     Abstract available


    July 2017
  6. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Text format     Abstract available


  7. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Text format     Abstract available


  8. CHO I, O Hartaigh B, Gransar H, Valenti V, et al
    Prognostic implications of coronary artery calcium in the absence of coronary artery luminal narrowing.
    Atherosclerosis. 2017;262:185-190.
    PubMed     Text format     Abstract available


  9. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Text format     Abstract available


    June 2017
  10. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Text format     Abstract available


  11. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Text format     Abstract available


  12. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Text format     Abstract available


  13. TERAMOTO T, Daida H, Ikewaki K, Arai H, et al
    Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Atherosclerosis. 2017;261:69-77.
    PubMed     Text format     Abstract available


  14. ARAI H, Yamashita S, Yokote K, Araki E, et al
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipida
    Atherosclerosis. 2017;261:144-152.
    PubMed     Text format     Abstract available


    May 2017
  15. HAGENSEN MK, Mortensen MB, Kjolby M, Stillits NL, et al
    Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta.
    Atherosclerosis. 2017;263:7-14.
    PubMed     Text format     Abstract available


  16. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Text format     Abstract available


  17. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Text format     Abstract available


  18. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Text format     Abstract available


  19. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Text format     Abstract available


    April 2017
  20. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Text format     Abstract available


  21. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Text format     Abstract available


  22. HIGUCHI S, Kabeya Y, Kato K
    Visceral-to-subcutaneous fat ratio is independently related to small and large cerebrovascular lesions even in healthy subjects.
    Atherosclerosis. 2017;259:41-45.
    PubMed     Text format     Abstract available


    March 2017
  23. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Text format     Abstract available


  24. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Text format     Abstract available


    February 2017
  25. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available


  26. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available


  27. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Text format     Abstract available


  28. DI COSTANZO A, D'Erasmo L, Polimeni L, Baratta F, et al
    Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage.
    Atherosclerosis. 2017;257:232-239.
    PubMed     Text format     Abstract available


    January 2017
  29. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Text format     Abstract available


  30. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Text format     Abstract available


  31. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Text format     Abstract available


  32. NONIN S, Iwata S, Sugioka K, Fujita S, et al
    Plaque surface irregularity and calcification length within carotid plaque predict secondary events in patients with coronary artery disease.
    Atherosclerosis. 2017;256:29-34.
    PubMed     Text format     Abstract available


  33. ANDREOZZI F, Mannino GC, Perticone M, Perticone F, et al
    Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile.
    Atherosclerosis. 2017;256:15-20.
    PubMed     Text format     Abstract available


    December 2016
  34. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Text format     Abstract available


  35. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Text format     Abstract available


  36. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Text format     Abstract available


    November 2016
  37. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Text format     Abstract available


    October 2016
  38. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Text format     Abstract available


  39. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Text format     Abstract available


  40. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Text format     Abstract available


  41. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Text format     Abstract available


    September 2016
  42. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Text format     Abstract available


  43. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Text format     Abstract available


  44. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Text format     Abstract available


    August 2016
  45. ALONSO R, Mata P, Muniz O, Fuentes-Jimenez F, et al
    PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Atherosclerosis. 2016 Aug 27. pii: S0021-9150(16)31306.
    PubMed     Text format     Abstract available


  46. GRENKOWITZ T, Kassner U, Wuhle-Demuth M, Salewsky B, et al
    Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Atherosclerosis. 2016;253:88-93.
    PubMed     Text format     Abstract available


    July 2016
  47. WATTS GF, Pang J, Chan DC, Brunt JN, et al
    Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Atherosclerosis. 2016;252:82-87.
    PubMed     Text format     Abstract available


  48. TORVIK K, Narverud I, Ottestad I, Svilaas A, et al
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;252:21-27.
    PubMed     Text format     Abstract available


  49. SCHOFIELD J, Kwok S, France M, Capps N, et al
    Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Atherosclerosis. 2016 Jul 10. pii: S0021-9150(16)30308.
    PubMed     Text format     Abstract available


  50. SJOUKE B, Defesche JC, de Randamie JS, Wiegman A, et al
    Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2016;251:263-265.
    PubMed     Text format     Abstract available


    May 2016
  51. SILVA PR, Jannes CE, Marsiglia JD, Krieger JE, et al
    Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Atherosclerosis. 2016;250:144-150.
    PubMed     Text format     Abstract available


  52. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Text format     Abstract available


  53. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


  54. ZHOU T, Ding JW, Wang XA, Zheng XX, et al
    Long noncoding RNAs and atherosclerosis.
    Atherosclerosis. 2016;248:51-61.
    PubMed     Text format     Abstract available


  55. PAN L, Yang Z, Wu Y, Yin RX, et al
    The prevalence, awareness, treatment and control of dyslipidemia among adults in China.
    Atherosclerosis. 2016;248:2-9.
    PubMed     Text format     Abstract available


    April 2016
  56. KRAUZOVA E, Kracmerova J, Rossmeislova L, Malisova L, et al
    Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women.
    Atherosclerosis. 2016;250:151-157.
    PubMed     Text format     Abstract available


  57. HUANG Y, Xu M, Xie L, Wang T, et al
    Obesity and peripheral arterial disease: A Mendelian Randomization analysis.
    Atherosclerosis. 2016;247:218-24.
    PubMed     Text format     Abstract available


  58. KOLODZIEJCZAK M, Navarese EP
    Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Atherosclerosis. 2016;247:189-92.
    PubMed     Text format     Abstract available


    March 2016
  59. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Text format     Abstract available


  60. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Text format     Abstract available


  61. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Text format     Abstract available


  62. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Text format     Abstract available


  63. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Text format     Abstract available


  64. ROTLLAN N, Price N, Pati P, Goedeke L, et al
    microRNAs in lipoprotein metabolism and cardiometabolic disorders.
    Atherosclerosis. 2016;246:352-60.
    PubMed     Text format     Abstract available


  65. EL TAHLAWI M, Sakrana A, Elmurr A, Gouda M, et al
    The relation between coronary tortuosity and calcium score in patients with chronic stable angina and normal coronaries by CT angiography.
    Atherosclerosis. 2016;246:334-7.
    PubMed     Text format     Abstract available


  66. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  67. PEDERSEN LR, Olsen RH, Anholm C, Walzem RL, et al
    Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial.
    Atherosclerosis. 2016;246:221-8.
    PubMed     Text format     Abstract available


  68. ESCATE R, Padro T, Badimon L
    LDL accelerates monocyte to macrophage differentiation: Effects on adhesion and anoikis.
    Atherosclerosis. 2016;246:177-86.
    PubMed     Text format     Abstract available


  69. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  70. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    February 2016
  71. AMOR AJ, Catalan M, Perez A, Herreras Z, et al
    Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis.
    Atherosclerosis. 2016;247:161-169.
    PubMed     Text format     Abstract available


  72. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Text format     Abstract available


  73. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Text format     Abstract available


    January 2016
  74. LATET SC, Van Craenenbroeck AH, Van Herck PL, Van Craenenbroeck EM, et al
    A critical view of monocyte subpopulations in human hypercholesterolemia.
    Atherosclerosis. 2016 Jan 14. pii: S0021-9150(16)30021.
    PubMed     Text format    


  75. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Text format     Abstract available


  76. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  77. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


    December 2015
  78. RASMUSSEN KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R, et al
    Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population.
    Atherosclerosis. 2015;246:63-70.
    PubMed     Text format     Abstract available


  79. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Text format     Abstract available


  80. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Text format     Abstract available


    October 2015
  81. BASU A, Jenkins AJ, Zhang Y, Stoner JA, et al
    Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
    Atherosclerosis. 2015;244:93-100.
    PubMed     Text format     Abstract available


  82. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.
    PubMed     Text format    


  83. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Text format     Abstract available


    September 2015
  84. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Text format     Abstract available


  85. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.
    PubMed     Text format    


  86. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Text format     Abstract available


  87. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Text format     Abstract available


  88. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Text format     Abstract available


  89. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Text format     Abstract available


    August 2015
  90. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Text format     Abstract available


    July 2015
  91. BOS S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, et al
    Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Atherosclerosis. 2015;242:226-229.
    PubMed     Text format     Abstract available


  92. ISHIKAWA T, Ayaori M, Uto-Kondo H, Nakajima T, et al
    High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease.
    Atherosclerosis. 2015;242:318-322.
    PubMed     Text format     Abstract available


  93. PEREIRA C, Miname MH, Makdisse MR, Watanabe C, et al
    Peripheral arterial disease in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;242:174-178.
    PubMed     Text format     Abstract available


  94. STOCK J, Hayes C
    Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.
    Atherosclerosis. 2015;242:277-280.
    PubMed     Text format    


  95. GALEMA-BOERS JM, Versmissen J, Roeters van Lennep HW, Dusault-Wijkstra JE, et al
    Cascade screening of familial hypercholesterolemia must go on.
    Atherosclerosis. 2015;242:415-417.
    PubMed     Text format     Abstract available


  96. KOTUR-STEVULJEVIC J, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Stefanovic A, et al
    Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients.
    Atherosclerosis. 2015;241:192-8.
    PubMed     Text format     Abstract available


  97. TACHIKAWA R, Koyasu S, Matsumoto T, Hamada S, et al
    Obstructive sleep apnea and abdominal aortic calcification: Is there an association independent of comorbid risk factors?
    Atherosclerosis. 2015;241:6-11.
    PubMed     Text format     Abstract available


    June 2015
  98. BARRIOS C, Pascual J, Otero S, Soler MJ, et al
    Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Atherosclerosis. 2015;242:37-44.
    PubMed     Text format     Abstract available


  99. KWON M, Han SM, Kim DI, Rhee MY, et al
    Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;242:8-12.
    PubMed     Text format     Abstract available


  100. AHN HY, Kim M, Chae JS, Ahn YT, et al
    Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia.
    Atherosclerosis. 2015;241:649-656.
    PubMed     Text format     Abstract available


  101. MINICOCCI I, Prisco C, Montali A, Di Costanzo A, et al
    Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach.
    Atherosclerosis. 2015;242:618-624.
    PubMed     Text format     Abstract available


  102. ITO MK
    Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature.
    Atherosclerosis. 2015 Jun 11. pii: S0021-9150(15)01366.
    PubMed     Text format     Abstract available


  103. BESSELING J, Sjouke B, Kastelein JJ
    Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).
    Atherosclerosis. 2015;241:597-606.
    PubMed     Text format     Abstract available


  104. AUSCHER S, Heinsen L, Nieman K, Vinther KH, et al
    Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography.
    Atherosclerosis. 2015;241:579-587.
    PubMed     Text format     Abstract available


  105. BRAAMSKAMP MJ, Kusters DM, Wiegman A, Avis HJ, et al
    Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
    Atherosclerosis. 2015;241:427-432.
    PubMed     Text format     Abstract available


  106. THOMPSON GR
    Obituary of Dr N.B. Myant.
    Atherosclerosis. 2015;240:437-8.
    PubMed     Text format    


  107. ASAKAWA T, Hayashi T, Tanaka Y, Joki N, et al
    Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease.
    Atherosclerosis. 2015;240:535-43.
    PubMed     Text format     Abstract available


  108. GERARDS MC, Terlou RJ, Yu H, Koks CH, et al
    Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Atherosclerosis. 2015;240:415-23.
    PubMed     Text format     Abstract available


    May 2015
  109. MASANA L, Pedro-Botet J, Civeira F
    IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Atherosclerosis. 2015;240:161-2.
    PubMed     Text format    


  110. ZHANG T, Zhang C, Zhang Y, Tang F, et al
    Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Atherosclerosis. 2015;240:144-8.
    PubMed     Text format     Abstract available


  111. KOOPAL C, Retterstol K, Sjouke B, Hovingh GK, et al
    Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Atherosclerosis. 2015;240:90-7.
    PubMed     Text format     Abstract available


  112. RABACCHI C, Pisciotta L, Cefalu AB, Noto D, et al
    Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
    Atherosclerosis. 2015;241:79-86.
    PubMed     Text format     Abstract available


    April 2015
  113. DE BACKER G, Besseling J, Chapman J, Hovingh GK, et al
    Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
    Atherosclerosis. 2015;241:169-175.
    PubMed     Text format     Abstract available


  114. ODA E
    Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population.
    Atherosclerosis. 2015;241:1-5.
    PubMed     Text format     Abstract available


  115. WATTS GF, Pang J, Santos RD
    Europe aspires to set the record straight on familial hypercholesterolaemia.
    Atherosclerosis. 2015 Apr 20. pii: S0021-9150(15)00234.
    PubMed     Text format    


  116. UENO Y, Yamashiro K, Tanaka Y, Watanabe M, et al
    Rosuvastatin may stabilize atherosclerotic aortic plaque: transesophageal echocardiographic study in the EPISTEME trial.
    Atherosclerosis. 2015;239:476-82.
    PubMed     Text format     Abstract available


  117. NUOTIO J, Oikonen M, Magnussen CG, Viikari JS, et al
    Adult dyslipidemia prediction is improved by repeated measurements in childhood and young adulthood. The Cardiovascular Risk in Young Finns Study.
    Atherosclerosis. 2015;239:350-7.
    PubMed     Text format     Abstract available


    March 2015
  118. STEFANUTTI C, Blom DJ, Averna MR, Meagher EA, et al
    The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Atherosclerosis. 2015;240:408-414.
    PubMed     Text format     Abstract available


  119. GUARDIOLA M, Cofan M, de Castro-Oros I, Cenarro A, et al
    APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.
    Atherosclerosis. 2015;240:98-104.
    PubMed     Text format     Abstract available


  120. DESCAMPS O, Tomassini JE, Lin J, Polis AB, et al
    Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
    Atherosclerosis. 2015;240:482-489.
    PubMed     Text format     Abstract available


  121. HARALAMBOS K, Whatley SD, Edwards R, Gingell R, et al
    Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Atherosclerosis. 2015;240:190-196.
    PubMed     Text format     Abstract available


  122. DEROSA G, Romano D, D'Angelo A, Maffioli P, et al
    Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses.
    Atherosclerosis. 2015;239:87-92.
    PubMed     Text format     Abstract available


  123. MEKONNEN G, Corban MT, Hung OY, Eshtehardi P, et al
    Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Atherosclerosis. 2015;239:55-60.
    PubMed     Text format     Abstract available


  124. ALIS R, Sanchis-Gomar F, Risso-Ballester J, Perez-Quilis C, et al
    Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis.
    Atherosclerosis. 2015;239:38-42.
    PubMed     Text format     Abstract available


  125. ODA E
    Cross-sectional and longitudinal associations between serum bilirubin and dyslipidemia in a health screening population.
    Atherosclerosis. 2015;239:31-7.
    PubMed     Text format     Abstract available


  126. HENDRIKS EJ, de Jong PA, van der Graaf Y, Mali WP, et al
    Breast arterial calcifications: a systematic review and meta-analysis of their determinants and their association with cardiovascular events.
    Atherosclerosis. 2015;239:11-20.
    PubMed     Text format     Abstract available


    February 2015
  127. TASKINEN MR, Boren J
    New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Atherosclerosis. 2015;239:483-495.
    PubMed     Text format     Abstract available


  128. KADOYA M, Koyama H, Kurajoh M, Kanzaki A, et al
    Sleep, cardiac autonomic function, and carotid atherosclerosis in patients with cardiovascular risks: HSCAA study.
    Atherosclerosis. 2015;238:409-14.
    PubMed     Text format     Abstract available


  129. GARCIA-SANCHEZ C, Posadas-Romero C, Posadas-Sanchez R, Carreon-Torres E, et al
    Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores.
    Atherosclerosis. 2015;238:250-5.
    PubMed     Text format     Abstract available


  130. SHIMIZU M, Furusyo N, Mitsumoto F, Takayama K, et al
    Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS).
    Atherosclerosis. 2015;238:207-12.
    PubMed     Text format     Abstract available


    January 2015
  131. DONG B, Singh AB, Azhar S, Seidah NG, et al
    High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
    Atherosclerosis. 2015;239:364-374.
    PubMed     Text format     Abstract available


  132. FUTEMA M, Kumari M, Boustred C, Kivimaki M, et al
    Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?
    Atherosclerosis. 2015;239:295-298.
    PubMed     Text format     Abstract available


  133. LEFORT B, Saheb S, Bruckert E, Giraud C, et al
    Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;239:158-162.
    PubMed     Text format     Abstract available


    December 2014
  134. BELL DA, Pang J, Burrows S, Bates TR, et al
    Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience.
    Atherosclerosis. 2014;239:93-100.
    PubMed     Text format     Abstract available


  135. WENG SF, Kai J, Andrew Neil H, Humphries SE, et al
    Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).
    Atherosclerosis. 2014;238:336-343.
    PubMed     Text format     Abstract available


    November 2014
  136. HIDDINK L, Dallinga-Thie GM, Hovingh GK, de Visser MC, et al
    Annexin A5 haplotypes in familial hypercholesterolemia: Lack of association with carotid intima-media thickness and cardiovascular disease risk.
    Atherosclerosis. 2014;238:195-200.
    PubMed     Text format     Abstract available


  137. LAHTINEN AM, Havulinna AS, Jula A, Salomaa V, et al
    Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population.
    Atherosclerosis. 2014;238:64-69.
    PubMed     Text format     Abstract available


  138. JANNES CE, Santos RD, de Souza Silva PR, Turolla L, et al
    Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects.
    Atherosclerosis. 2014;238:101-107.
    PubMed     Text format     Abstract available


  139. FADINI GP, Simoni F, Cappellari R, Vitturi N, et al
    Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2014;237:805-808.
    PubMed     Text format     Abstract available


    October 2014
  140. MOLLAKI V, Progias P, Drogari E
    Familial Hypercholesterolemia in Greek children and their families: Genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum.
    Atherosclerosis. 2014;237:798-804.
    PubMed     Text format     Abstract available


  141. ZENG RX, Li XL, Zhang MZ, Guo YL, et al
    Non-HDL cholesterol is a better target for predicting periprocedural myocardial injury following percutaneous coronary intervention in type 2 diabetes.
    Atherosclerosis. 2014;237:536-543.
    PubMed     Text format     Abstract available


    September 2014
  142. SKOUMAS J, Liontou C, Chrysohoou C, Masoura C, et al
    Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia.
    Atherosclerosis. 2014;237:140-145.
    PubMed     Text format     Abstract available


  143. FOLSE HJ, Goswami D, Rengarajan B, Budoff M, et al
    Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Atherosclerosis. 2014;236:154-61.
    PubMed     Text format     Abstract available


  144. BOLLI P
    Treatment of dyslipidemia: the problem of reaching the goal.
    Atherosclerosis. 2014;236:142-3.
    PubMed     Text format     Abstract available


    July 2014
  145. LIU JJ, Sum CF, Tavintharan S, Yeoh LY, et al
    Obesity is a determinant of arterial stiffness independent of traditional risk factors in Asians with young-onset type 2 diabetes.
    Atherosclerosis. 2014;236:286-291.
    PubMed     Text format     Abstract available


  146. PRENNER SB, Mulvey CK, Ferguson JF, Rickels MR, et al
    Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.
    Atherosclerosis. 2014;236:244-250.
    PubMed     Text format     Abstract available


    June 2014
  147. JAHAGIRDAR R, Zhang H, Azhar S, Tobin J, et al
    A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.
    Atherosclerosis. 2014;236:91-100.
    PubMed     Text format     Abstract available


  148. MABUCHI H, Nohara A, Noguchi T, Kobayashi J, et al
    Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Atherosclerosis. 2014;236:54-61.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: